forum
LALPATHLAB Share Price Discussion
Dr. Lal Pathlabs Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
LALPATHLAB Share Price *
1,239 -2 (-0.16%)
* (quote may be delayed)
LALPATHLAB Discussion Forum
ICICI Prudential, D-Mart among Top 5 stocks that can give 10-16% return; here’s why
If the Nifty slips below 10,746, the next support is placed at 10,636. A break below 10,636 will signal a continuation of the decline and may take the index towards 10,450 levels.
If the Nifty slips below 10,746, the next support is placed at 10,636. A break below 10,636 will signal a continuation of the decline and may take the index towards 10,450 levels.
Moneycontrol
Like
reply
Reply
share
Share
'Equity market selloff has boosted demand for Gold and Silver'
The overall demand for Gold and silver investments have also increased in the current period to an all-time high, due to volatile Indian equity markets and further concerns about the health of the Indian economy.
The overall demand for Gold and silver investments have also increased in the current period to an all-time high, due to volatile Indian equity markets and further concerns about the health of the Indian economy.
Moneycontrol
Like
reply
Reply
share
Share
30 stocks hit 52-week high; is TINA factor driving these shares?
Stocks which bucked the trend include names like Abbott India, Bata India, HDFC AMC, ICICI Lombard, InterGlobe Aviation, Infosys, Petronet LNG, TCS etc. among others.
Stocks which bucked the trend include names like Abbott India, Bata India, HDFC AMC, ICICI Lombard, InterGlobe Aviation, Infosys, Petronet LNG, TCS etc. among others.
Moneycontrol
Like
reply
Reply
share
Share
Infosys, HUL among top Nifty stocks that are in buy zone; here’s why
Confirmation of the breakdown will come once the index starts to trade below 10,782. A break below 10,782 would take the Nifty towards the next support which is placed at 10,580 levels
Confirmation of the breakdown will come once the index starts to trade below 10,782. A break below 10,782 would take the Nifty towards the next support which is placed at 10,580 levels
Moneycontrol
Like
reply
Reply
share
Share
Accumulate Dr. Lal PathLabs; target of Rs 1120: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1120 in its research report dated August 14, 2019.
Prabhudas Lilladher recommended accumulate rating on Dr. Lal PathLabs with a target price of Rs 1120 in its research report dated August 14, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Dr Lal Pathlabs Q4 PAT seen up 17.6% YoY to Rs. 58.1 cr: Kotak
Like
reply
Reply
share
Share
Nearly 300 BSE500 stocks trade below 200-DMA; time to sell?
Like
reply
Reply
share
Share
Dr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas Lilladher
Like
reply
Reply
share
Share
Dr Lal PathLab Standalone March 2019 Net Sales at Rs 292.00 crore, up 12.96% Y-o-Y
Like
reply
Reply
share
Share
LALPATHLAB NSE CASH LOOKING GOOD TO BUY ABOVE 985, FOR TARGET 995
Like
reply
Reply (4)
share
Share
Latest replies
Stop loss ?
990 LALPATHLAB 🔥🔥🔥
991.5 🔥🔥🔥
it's called catching at bottom 💪💪💪
992.35 👍👍👍
Dr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak
Like
reply
Reply
share
Share
Metropolis Healthcare hits record high after Damani’s Bright Star picks 7 lakh shares
Like
reply
Reply
share
Share
Metropolis Healthcare to debut on April 15; will it be a bumper listing?
Like
reply
Reply
share
Share
Dr. Lal Pathlabs Q4 PAT seen up 26.2% YoY to Rs. 50.6 cr: Prabhudas Lilladher
Like
reply
Reply
share
Share
75 BSE 500 cos can pay Rs 1.1 lakh crore more to shareholders: Report
Like
reply
Reply
share
Share
Dr Lal PathLabs gains 3% on acquisition of Bawankar Pathology
Like
reply
Reply
share
Share
Metropolis to focus on wellness, specialty tests & acquisitions to grow biz
Like
reply
Reply
share
Share
Stocks in the news: Jet Airways, RIL, Indian Hume Pipe, IRB Infra, Hero Moto, Aurobindo, Tata Motors
Like
reply
Reply
share
Share
Trade Setup for Tuesday: Top 15 things to know before Opening Bell
Like
reply
Reply
share
Share
Accumulate Dr. Lal PathLabs; target of Rs 1070: Prabhudas Lilladher
Like
reply
Reply
share
Share
Dr Lal PathLab Standalone December 2018 Net Sales at Rs 282.80 crore, up 11.16% Y-o-Y
Like
reply
Reply
share
Share
Dr Lalpath Lab reported lower than Bloomberg expected Q3 results. Company reported Q3 net profit Rs443mn (up 27% YoY) - Bloomberg expectation Rs486mn, other income Rs150mn vs Rs53mn, EBITDA Rs656mn (up 15.6% YoY), EBITDA margin up 88bps at 22.4% and income Rs2.93bn (up 11.3% Yo...
Read more...
Like
reply
Reply
share
Share
Edelweiss maintains defensive portfolio, bets on 8 largecaps and 6 midcap stocks
Like
reply
Reply
share
Share
Edelweiss cautious on market, maintains defensive portfolio; 8 large and 6 midcap bets
Like
reply
Reply
share
Share
Market Headstart: Nifty likely to open higher; 3 stocks which could give 7-9% return
Like
reply
Reply
share
Share
Podcast | Stock picks of the day: Lupin, Hindalco among top buys for short-term trade
Like
reply
Reply
share
Share
A morning walk down Dalal Street | Expect consolidation in near term with stiff resistance at 11,100
Like
reply
Reply
share
Share
Accumulate Dr. Lal PathLabs; target of Rs 1009: Prabhudas Lilladher
Like
reply
Reply
share
Share
Brokerages remain mixed on Dr Lal PathLabs Q2 show; Citi maintains buy rating
Like
reply
Reply
share
Share
Lal PathLabs net up 12.8% at Rs 57.4 cr
Like
reply
Reply
share
Share
Dr Lal PathLab Standalone September 2018 Net Sales at Rs 307.20 crore, up 14.07% Q-o-Q
Like
reply
Reply
share
Share
- NewsBotSep 5 4:23 PMICICI Prudential, D-Mart among Top 5 stocks that can give 10-16% return; here’s whyMoneycontrolNewsBotSep 4 4:48 PM'Equity market selloff has boosted demand for Gold and Silver'MoneycontrolNewsBotSep 4 3:38 PM30 stocks hit 52-week high; is TINA factor driving these shares?MoneycontrolNewsBotAug 22 6:13 PMInfosys, HUL among top Nifty stocks that are in buy zone; here’s whyMoneycontrolNewsBotAug 14 10:08 PMAccumulate Dr. Lal PathLabs; target of Rs 1120: Prabhudas Lilladhermoneycontrol.comNewsBotJul 15 8:38 PMDr Lal Pathlabs Q4 PAT seen up 17.6% YoY to Rs. 58.1 cr: KotakNewsBotJul 15 7:38 PMNearly 300 BSE500 stocks trade below 200-DMA; time to sell?NewsBotJul 12 10:23 PMDr. Lal PathLabs Q1 PAT seen up 5.5% YoY to Rs. 52.1 cr: Prabhudas LilladherNewsBotMay 17 9:43 PMDr Lal PathLab Standalone March 2019 Net Sales at Rs 292.00 crore, up 12.96% Y-o-YNewsBotApr 17 8:43 PMDr Lal Pathlabs Q4 PAT seen up 28.3% YoY to Rs. 51.4 cr: Kotak
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.